tru Independence’s AbbVie ABBV Stock Holding History

tru Independence’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$410K	Sell	1,566 -82	-5%	-$21K	0.18%	66
2026 Q2	$415K	Buy	1,648 +59	+4%	+$12.7K	0.18%	65
2026 Q1	$346K	Sell	1,589 -17,848	-92%	-$3.96M	0.17%	73
2025 Q4	$4.44M	Sell	19,437 -32	-0.2%	-$7.29K	1.12%	43
2025 Q3	$4.51M	Buy	19,469 +155	+0.8%	+$31.6K	1.17%	42
2025 Q2	$3.59M	Buy	19,314 +207	+1%	+$38.5K	1.04%	44
2025 Q1	$4M	Buy	19,107 +799	+4%	+$155K	1.24%	39
2024 Q4	$3.25M	Sell	18,308 -164	-0.9%	-$30.2K	1.02%	42
2024 Q3	$3.65M	Sell	18,472 -16,919	-48%	-$3.16M	1.07%	46
2024 Q2	$6.07M	Buy	+35,391	New	+$5.86M	1.83%	21
2021 Q1	–	Sell	-1,434	Closed	-$154	–	298
2020 Q4	$154	Buy	1,434 +139	+11%	+$13.4K	﹤0.01%	439
2020 Q3	$113K	Sell	1,295 -9,834	-88%	-$926K	0.03%	182
2020 Q2	$1.09M	Sell	11,129 -2,747	-20%	-$242K	0.16%	106
2020 Q1	$1.06M	Hold	13,876	–	–	0.17%	95
2019 Q4	$1.06M	Buy	+13,876	New	+$1.15M	0.15%	109

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $2.5B AUM 20.77% 1-Year Est. Return

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

tru Independence's ABBV Position: Q3 2026 in Review

tru Independence reduced its AbbVie (ABBV) stake by 5% in Q3 2026, selling an estimated $21K and leaving 1,566 shares worth $410K. The position accounts for 0.18% of the portfolio, ranked #66.

tru Independence first reported a position in ABBV in Q4 2019 and has held it in 15 quarters since. The position peaked at $6.07M in Q2 2024. 1,436 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

tru Independence held 1,566 shares of AbbVie worth $410K as of Q3 2026.
tru Independence sold 82 AbbVie shares in Q3 2026, an estimated $21K.
AbbVie made up 0.18% of tru Independence's portfolio in Q3 2026, its #66 holding.
tru Independence first reported a position in AbbVie in Q4 2019 and has held it in 15 quarters since.
tru Independence's AbbVie position peaked at $6.07M in Q2 2024.
1,436 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on tru Independence's 13F filing for Q3 2026, filed 20 Oct 2026.